HBV-IN-22

• UNSPSC Description:

  HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively[1].

• Target Antigen:

  DNA/RNA Synthesis; HBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/hbv-in-22.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCN(CCOC1=CC=C2N=C(N(C(C2=C1)=O)CC3=CC=CS3)SCC4=CC=CC=C4)CC

• Molecular Weight:

  479.66

• References & Citations:

  [1]Qiu J, et al. Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. Eur J Med Chem. 2020 Nov 1;205:112581.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2338573-94-5